The aryl hydrocarbon receptor: A crucial mediator in ocular disease pathogenesis and therapeutic target

IF 3 2区 医学 Q1 OPHTHALMOLOGY
Juanjuan Ji , Chanyu Xiong , Huining Yang , Zhilin Jiang , Yun Zhang , Xiao Wang , Tianshu Yu , Qiong Li , Shikai Zhu , Yu Zhou
{"title":"The aryl hydrocarbon receptor: A crucial mediator in ocular disease pathogenesis and therapeutic target","authors":"Juanjuan Ji ,&nbsp;Chanyu Xiong ,&nbsp;Huining Yang ,&nbsp;Zhilin Jiang ,&nbsp;Yun Zhang ,&nbsp;Xiao Wang ,&nbsp;Tianshu Yu ,&nbsp;Qiong Li ,&nbsp;Shikai Zhu ,&nbsp;Yu Zhou","doi":"10.1016/j.exer.2024.110144","DOIUrl":null,"url":null,"abstract":"<div><div>The aryl hydrocarbon receptor (AHR) is a pivotal nuclear receptor involved in mediating cellular responses to a wide range of environmental pollutants and endogenous ligands. AHR plays a central role in regulating essential physiological processes, including xenobiotic metabolism, immune response modulation, cell cycle control, tumorigenesis, and developmental events. Recent studies have identified AHR as a critical mediator and a potential therapeutic target in the pathogenesis of ocular diseases. This review provides a thorough analysis of the various functions of AHR signalling in the ocular environment, with a specific emphasis on its effects on the retina, retinal pigment epithelium (RPE), choroid, and cornea. We provide a detailed discussion on the molecular mechanisms through which AHR integrates environmental and endogenous signals, influencing the development and progression of age-related macular degeneration (AMD), retinitis pigmentosa, uveitis, and other major ocular disorders. Furthermore, we evaluate the therapeutic potential of modulating AHR activity through novel ligands and agonists as a strategy for treating eye diseases. Understanding the molecular mechanisms of AHR in ocular tissues may facilitate the development of AHR-targeted therapies, which is crucial for addressing the pressing clinical demand for novel treatment strategies in ocular diseases.</div></div>","PeriodicalId":12177,"journal":{"name":"Experimental eye research","volume":"249 ","pages":"Article 110144"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental eye research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S001448352400366X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The aryl hydrocarbon receptor (AHR) is a pivotal nuclear receptor involved in mediating cellular responses to a wide range of environmental pollutants and endogenous ligands. AHR plays a central role in regulating essential physiological processes, including xenobiotic metabolism, immune response modulation, cell cycle control, tumorigenesis, and developmental events. Recent studies have identified AHR as a critical mediator and a potential therapeutic target in the pathogenesis of ocular diseases. This review provides a thorough analysis of the various functions of AHR signalling in the ocular environment, with a specific emphasis on its effects on the retina, retinal pigment epithelium (RPE), choroid, and cornea. We provide a detailed discussion on the molecular mechanisms through which AHR integrates environmental and endogenous signals, influencing the development and progression of age-related macular degeneration (AMD), retinitis pigmentosa, uveitis, and other major ocular disorders. Furthermore, we evaluate the therapeutic potential of modulating AHR activity through novel ligands and agonists as a strategy for treating eye diseases. Understanding the molecular mechanisms of AHR in ocular tissues may facilitate the development of AHR-targeted therapies, which is crucial for addressing the pressing clinical demand for novel treatment strategies in ocular diseases.
芳基烃受体:眼部疾病发病机制和靶向治疗的关键介质。
芳基烃受体(AHR)是一种关键的核受体,参与介导细胞对多种环境污染物和内源性配体的反应。AHR 在调节基本生理过程中发挥着核心作用,包括异生物代谢、免疫反应调节、细胞周期控制、肿瘤发生和发育事件。最近的研究发现,AHR 是眼部疾病发病机制中的关键介质和潜在治疗靶点。本综述深入分析了 AHR 信号在眼部环境中的各种功能,特别强调了它对视网膜、视网膜色素上皮(RPE)、脉络膜和角膜的影响。我们详细讨论了 AHR 整合环境和内源性信号,影响老年性黄斑变性(AMD)、视网膜色素变性、葡萄膜炎和其他主要眼部疾病的发生和发展的分子机制。此外,我们还评估了通过新型配体和激动剂调节 AHR 活性作为眼科疾病治疗策略的治疗潜力。了解 AHR 在眼部组织中的分子机制有助于开发 AHR 靶向疗法,这对于满足临床对眼部疾病新型治疗策略的迫切需求至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Experimental eye research
Experimental eye research 医学-眼科学
CiteScore
6.80
自引率
5.90%
发文量
323
审稿时长
66 days
期刊介绍: The primary goal of Experimental Eye Research is to publish original research papers on all aspects of experimental biology of the eye and ocular tissues that seek to define the mechanisms of normal function and/or disease. Studies of ocular tissues that encompass the disciplines of cell biology, developmental biology, genetics, molecular biology, physiology, biochemistry, biophysics, immunology or microbiology are most welcomed. Manuscripts that are purely clinical or in a surgical area of ophthalmology are not appropriate for submission to Experimental Eye Research and if received will be returned without review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信